Pendium

Step 1 of 9

Zimmer Biomet owns the orthopedic conversation in AI answers, but the digital health race is tightening.

With a visibility score of 82, your lead is real. The strategy now is about compounding that authority across robotics and patient data before incumbents can catch up.

Zimmer Biomet's baseline score
82/100
Excellent

Zimmer Biomet enjoys dominant AI visibility, particularly in reconstructive surgery and robotics. While Stryker remains a fierce competitor in AI-driven shortlists, Zimmer Biomet is a canonical reference for joint replacement. The next frontier is winning the digital-care narrative where specialized software startups currently have an outsized voice.

What we see
  • Zimmer Biomet is a top-three recommendation in almost every AI query regarding knee and hip implants.
  • The ROSA system has high visibility in technical comparisons, often appearing as the primary alternative to Stryker's Mako.
  • Visibility in 'sports medicine' is lower than in 'reconstructive surgery,' leaving an opening for competitors like Arthrex.
  • Digital health mentions for 'mymobility' are strong but often tied to Apple, rather than Zimmer Biomet's independent platform authority.
  • The brand lacks conversational 'patient-first' content, causing AI to favor medical blogs for patient-intent prompts.
Business goals Zimmer Biomet is likely trying to hit
  • Increase adoption of the ROSA Robotics platform in community hospitals
  • Expand market share in the digital health and patient monitoring space
  • Defend leadership in the knee and hip replacement markets against Stryker
  • Win more integrated health system contracts through data-driven outcomes